Lv12
68 积分 2025-09-20 加入
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions
2小时前
待确认
《肺纤维化合并肺气肿综合征ATS/ERS/JRS/ALAT研究共识》解读(二)：定义、综合管理及未来研究重点
6天前
已完结
[Chinese expert consensus on multidisciplinary discussion of interstitial lung disease]
6天前
已完结
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
6天前
已完结
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II)
12天前
已关闭
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
29天前
已完结
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review
1个月前
已完结
中国干眼专家共识：检查和诊断（2020年）
1个月前
已完结
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
1个月前
已关闭
Safety, pharmacokinetics and pharmacodynamics of TQC3721, an innovative, dual PDE3 and PDE4 inhibitor, in healthy subjects and patients with chronic obstructive pulmonary disease: Randomised, double-blind, placebo-controlled phase I and IIa clinical trials
1个月前
已完结
皖公网安备34019202002308
